MapLight Therapeutics

US · MPLT #3723 by market cap Listed 2025

9.09 -0.27 -2.88%

Live - 5344 symbols - heartbeat 167s ago · 2026-10-08 10:00

Pre-market 9.06 -3.21%

After-hours 9.36 0.00%

Overnight 9.36 0.00%

Market cap: 505.18M
P/E (TTM): -1.80
P/B: 1.45
EPS: -3.66
Div yield: 0.00%
52W pos: 1%

Reader sentiment Are you bullish or bearish on MPLT?

Anonymous reader poll. Unscientific, not investment advice.

About MapLight Therapeutics

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.

Founded: 2018
CEO: Dr. Christopher A. Kroeger, M.D.
Employees: 133
Headquarters: Redwood City, California, United States of America
Fiscal year end: 12-31
Website: maplightrx.com

Company profile

Exchange: US
Symbol: MPLT
Market-cap rank: #3723
Listing date: 2025-10-27
Market cap: 505.18M
Float cap: 174.84M
Shares out: 55.58M
Float shares: 19.23M

Sectors & themes

Biotechnology IPOs

Browse all sectors & themes

Quote time 2026-10-08 10:00:31 · For reference only, not investment advice and not tailored to your situation.